多巴丝肼联合盐酸普拉克索对老年中晚期PD患者血清中Hcy浓度的影响及其临床意义.docVIP

多巴丝肼联合盐酸普拉克索对老年中晚期PD患者血清中Hcy浓度的影响及其临床意义 　　[摘要] 目的 探讨多巴丝肼联合森福罗（盐酸普拉克索）治疗老年中晚期帕金森病的效果及对同型半胱氨酸（homocysteine，Hcy）浓度的影响。 方法 回顾性分析2010年3月～2013年5月经我院收治的老年中晚期PD患者103例，根据用药方案分为单纯组和联合组，其中单纯组给予多巴丝肼治疗，联合组给予多巴丝肼片和森福罗（盐酸普拉克索片）治疗。临床疗效采用UPDRS评分评定，生活质量变化采用PDQ-39评分评定。并于治疗前及治疗2、6个月后检测两组患者血浆Hcy水平。 结果 治疗6个月后，联合组患者总有效率高达94.44%，与单纯组的69.39%比较，差异有统计学意义（P0.05）。 结论 多巴丝肼联合森福罗治疗老年中晚期帕金森病能显著提高治疗效果，改善患者的生活质量，且不加重多巴丝肼造成的高Hcy血症，值得临床作进一步推广。 　　[关键词] 多巴丝肼；森福罗；帕金森病；同型半胱氨酸 　　[中图分类号] R742.5 [文献标识码] A [文章编号] 1673-9701（2015）13-0016-03 　　[Abstract] Objective To investigate the treatment effect and impact on plasma homocysteine （Hcy） concentration of benserazide and senflor treating elderly patients with middle-late Parkinsons disease（PD）. Methods 103 elderly patients with middle-late PD were retrospectively analyzed in our hospital from March 2010 to May 2013，which divided into pure group and combined group according to treating method. Pure group was given dobutamine silk hydrazine treatment，combined group was given benserazide and senflor （pramipexole hydrochloride） treatment. Clinical efficacy was evaluated by UPDRS score and quality of life changes were rated by PDQ-39. Hcy before and after 6 months treatment of two groups was detected. Results After treated with 2， 6 months， effective rate of the combined group total was as high as 94.44%， was higher than the 69.39% of pure group， and the difference was statistically significant（P0.05）. Conclusion Benserazide combined senflor treating middle-late PD can significantly improve the effect of treatment， improve the patients quality of life， and do not increase high Hcy levels which is caused by benserazide， it’s worth of further clinical promotion. 　　[Key words] Benserazide； Senflor； Parkinsons disease； Plasma homocysteine 　　帕金森病（Parkinsons disease，PD）是临床较为常见的中枢神经系统性疾病，好发于老年人群，可使患者出现四肢不灵活、动作不协调、流涎及言语不清等症状，降低患者的日常生活能力。PD的发病机制尚未明确，主要与社会、药物、环境等因素有关，其病理改变是由于脑干黑质多巴胺能神经元减少引起的多巴胺丢失所致，目前主要通过合理选用药物和理疗控制或减轻症状，但尚无根治治疗方法[1]。多巴丝肼是临床上治疗PD的常用药物，能够有效减轻患者肢体震颤和肌强直